UBXinactive
Unity Biotechnology, Inc.
Biopharma developer (SEC filing verified)·Phase 2·CEO: Anirvan Ghosh
Ophthalmology
Run Unity Biotechnology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Unity Biotechnology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Governance
Frequently asked questions
Who is the CEO of Unity Biotechnology, Inc.?
Anirvan Ghosh is the chief executive officer of Unity Biotechnology, Inc. (UBX).
What therapeutic areas does Unity Biotechnology, Inc. focus on?
Unity Biotechnology, Inc. develops therapies across Ophthalmology.
923 companies304,846 SEC filings22,682 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.